Fusen Pharmaceutical Company Limited, an investment holding company, researches and develops, manufactures, and sells pharmaceutical products in the People’s Republic of China. The company’s product portfolio includes Shuanghuanglian-based cold medicines comprising Shuanghuanglian oral solutions and Shuanghuanglian injections; heat-clearing and detoxicating oral solutions; nicardipine hydrochloride injections; and other products. It also offers cardio cerebrovascular, blood pressure and sugar reduction, tonifying, qi-regulating, anti-anemia, antibacterial and anti-inflammatory, gastrointestinal tract, and expectorant cough category products. It also researches, develops, produces, and sells various proprietary Chinese medicines and western medicine products for the treatment of cold, fever, cardiovascular diseases, and anemia. In addition, the company offers business management and consulting services; and engages in the sale of construction material and electricity. Fusen Pharmaceutical Company Limited was founded in 2003 and is headquartered in Nanyang, China.
Metrics to compare | 1652 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship1652PeersSector | |
---|---|---|---|---|
P/E Ratio | −7.1x | −24.0x | −0.7x | |
PEG Ratio | 0.01 | 0.40 | 0.00 | |
Price/Book | 1.2x | 1.9x | 2.6x | |
Price / LTM Sales | 1.5x | 5.7x | 3.2x | |
Upside (Analyst Target) | - | 48.9% | 45.9% | |
Fair Value Upside | Unlock | −5.9% | 7.6% | Unlock |